293 related articles for article (PubMed ID: 34132875)
1. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
2. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
[TBL] [Abstract][Full Text] [Related]
3. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
4. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
[TBL] [Abstract][Full Text] [Related]
5. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
[TBL] [Abstract][Full Text] [Related]
6. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
7. Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.
Zhang ZX; Xv H; Du YN; Lv ZB; Yang ZH
BMC Gastroenterol; 2024 Mar; 24(1):117. PubMed ID: 38515017
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
9. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
12. Recurrence After Curative Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.
Wang W; Yang C; Zhu K; Yang L; Ding Y; Luo R; Zhu S; Chen C; Sun W; Zeng M; Rao SX
Liver Transpl; 2020 Jun; 26(6):751-763. PubMed ID: 31901208
[TBL] [Abstract][Full Text] [Related]
13. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
[TBL] [Abstract][Full Text] [Related]
14. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
PLoS One; 2020; 15(11):e0242344. PubMed ID: 33186378
[TBL] [Abstract][Full Text] [Related]
16. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]